

mRNA Therapeutics CDMO Market Competition Trends and Industry Positioning

The Business Research Company's mRNA Therapeutics CDMO Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, April 22, 2026

[/EINPresswire.com/](https://EINPresswire.com/) -- "The [mRNA therapeutics CDMO market](#) is

characterized by the presence of global contract development and manufacturing organizations, specialized nucleic acid manufacturing


firms, and emerging biotech service providers. Companies are focusing on advanced mRNA synthesis technologies, scalable lipid nanoparticle (LNP) delivery systems, integrated end-to-end manufacturing capabilities, and stringent regulatory-compliant quality frameworks to strengthen their market position and support the growing pipeline of mRNA-based therapeutics and vaccines. Understanding the competitive landscape is essential for stakeholders aiming to capitalize on outsourcing trends, secure strategic partnerships, and achieve long-term growth in the rapidly evolving mRNA therapeutics CDMO market.

Which Market Player Is Leading The mRNA Therapeutics CDMO Market?

•According to our research, Lonza Group led global sales in 2024 with a 5% market share. The company's biologics and cell & gene division, which is directly involved in the mRNA therapeutics CDMO market, offering integrated services across plasmid DNA production, mRNA synthesis, lipid nanoparticle (LNP) formulation, and aseptic fill-finish capabilities. It also provides end-to-end development and manufacturing solutions, supported by advanced process optimization technologies and regulatory-compliant quality systems to enable scalable and efficient commercialization of mRNA-based therapeutics and vaccines.

How Concentrated Is The mRNA Therapeutics CDMO Market?

•The market is fairly concentrated, with the top 10 players accounting for 36% of total market revenue in 2024. This level of concentration reflects the capital-intensive nature of mRNA manufacturing, the need for advanced technological capabilities, and strict regulatory



mRNA Therapeutics CDMO Market Report 2026

compliance requirements, which limit the number of fully integrated service providers. Leading companies such as Lonza Group, Thermo Fisher Scientific Inc. (Patheon), Samsung Biologics Co. Ltd., WuXi Biologics (WuXi Vaccines), Catalent, Inc. (Catalent Biologics Inc.), Danaher Corporation (Aldevron), Merck KGaA (Merck Millipore), AGC Biologics GmbH, GenScript Biotech Corporation (ProBio), and FUJIFILM Holdings Corporation (Fujifilm Pharmaceuticals U.S.A., Inc.) maintain a competitive advantage through their large-scale GMP manufacturing infrastructure, end-to-end mRNA development capabilities, expertise in lipid nanoparticle (LNP) formulation, and established partnerships with global biopharma companies. At the same time, emerging and specialized CDMOs are intensifying competition by offering flexible manufacturing solutions, niche technological expertise, and faster turnaround times. As demand for mRNA-based vaccines and therapeutics continues to expand, strategic collaborations, capacity expansions, and selective acquisitions are expected to further strengthen the position of leading players while supporting innovation and scalability across the evolving mRNA therapeutics CDMO market.

•Leading companies include:

- oLonza Group (5%)
- oThermo Fisher Scientific Inc. (Patheon) (5%)
- oSamsung Biologics Co. Ltd. (5%)
- oWuxi Biologics (WuXi Vaccines) (4%)
- oCatalent, Inc. (Catalent Biologics Inc.) (4%)
- oDanaher Corp.(Aldevron) (3%)
- oMerck KGaA (Merck Millipore) (3%)
- oAGC Biologics GmbH (2%)
- oGenscript Biotech Corp. (ProBio) (2%)
- oFUJIFILM Holdings Corporation (Fujifilm Pharmaceuticals U.S.A., Inc) (2%)

Request A Free Sample Of The [mRNA Therapeutics CDMO Market Report](https://www.thebusinessresearchcompany.com/sample_request?id=25841&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR)

https://www.thebusinessresearchcompany.com/sample_request?id=25841&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

Which Companies Are Leading Across Different Regions?

•North America: Novocol Pharma, Therapure Biopharma, BIOVECTRA, Aldevron, Ethris AG, Bionova Scientific Inc., Hongene Biotech Corporation, Lonza Group, Moderna, Thermo Fisher Scientific, Catalent, Inc., Merck KGaA, AGC Biologics, TriLink BioTechnologies LLC and Bio-Synthesis Inc. are leading companies in this region.

•Asia Pacific: Lonza Group, Corden Pharma Corp., Wuxi Biologics, Thermo Fisher Scientific, Catalent, Inc., Merck KGaA, Recipharm AB, Rentschler Biopharma SE, AGC Biologics GmbH, Samsung Biologics Co. Ltd., GC Biopharma, ST Pharm and Southern RNA are leading companies in this region.

•Western Europe: Recipharm AB, AGC Biologics, Lonza Group, Rentschler Biopharma, Catalent

Pharma Solutions and IDT Biologika are leading companies in this region.

- Eastern Europe: Richter-Helm BioLogics GmbH & Co. KG, Polpharma Biologics Group B.V. and Lonza Group are leading companies in this region.

- South America: Novartis' Brazilian, Insud Pharma Group, Eurofarma Laboratórios and Sinergium Biotech are leading companies in this region.

- Middle East: Samsung Biologics, Lonza Group, Thermo Fisher Scientific, SaudiVax Ltd. and Lifera are the leading companies in this region.

- Africa: Samsung Biologics, Lonza Group, Thermo Fisher Scientific, Biocina Pty Ltd and Biomay AG are the leading companies in this region.

What Are The Major Competitive Trends In The Market?

- Rapid, personalized mRNA manufacturing integrated with gene-editing technologies is transforming the mRNA therapeutics CDMO market by accelerating development timelines and enabling patient-specific treatments for rare and critical diseases.
- Example: In May 2025, Aldevron and Integrated DNA Technologies developed the world's first personalized mRNA-based CRISPR therapy for an infant with a rare urea cycle disorder, produced in just six months in collaboration with Acuitas Therapeutics.
- Its use of customized guide RNA, mRNA-encoded base editors, advanced safety testing, and lipid nanoparticle delivery enhances treatment precision, shortens manufacturing timelines, and supports the future commercialization of personalized genetic therapies.

Which Strategies Are Companies Adopting To Stay Ahead?

- Integrated Sequence Optimization And GMP Manufacturing Partnership Accelerates mRNA Program Development
- Advancement Of Next-Generation Lipid Nanoparticle Delivery Platforms
- Strategic Platform–Manufacturing Collaboration Accelerates Scalable mRNA Development
- Large-Scale Manufacturing Expansion Strengthens Regional mRNA Supply And Readiness

Access The Detailed mRNA Therapeutics CDMO Market Report Here

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr PR

Learn More About [The Business Research Company](https://www.thebusinessresearchcompany.com)

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: info@tbrc.info

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/907320791>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.